Goldman Sachs analyst Richard Felton initiated coverage of Fresenius Medical Care with a Buy rating and EUR 56 price target. Fresenius has not seen meaningful positive consensus earnings revisions since January 2019, but that is about to change, the analyst tells investors in a research note. The firm believes an easing of external cost pressure and new management focused on driving improved performance under a new operating model can begin to drive an upgrade cycle.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FMS: